Patent ID: 6518242
Filing Date: 2003-02-11
Classification: A61K,C07K

Abstract:
A compound of the formula:Lâ€²â€”Xâ€”Lâ€³whereinLâ€² an optionally-substituted vancomycin or N-desmethylvancomycin moiety of the formula: Lâ€³ is an optionally-substituted vancomycin or N-desmethylvancomycin moiety ligand of the formula: wherein [V] indicates the vancosamine nitrogen atom, [C] indicates the carboxy terminus, [R] indicates the resorcinol terminus and [N] indicates the amino terminus, and Lâ€² is attached to X at the carboxy terminus and Lâ€³ is attached to X at the vancosamine nitrogen atom; and further wherein R is hydrogen or methyl; and Lâ€² and Lâ€³ are optionally substituted at any hydroxyl, amino or carboxyl group not attached to the linker with Ra, where Rb at each ocurrence is selected from the group consisting of alkyl, haloalkyl, alkenyl, alkynyl, alkylaminoalkyl, cycloalkyl, alkanoyl, aryl, heteroaryl, heterocyclic and a saccharide group; or the carboxyl group of Lâ€³ is optionally substituted with â€”NRcRd or N-glucosamine to form an amide, where Rc and Rd are independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, alkanoyl, aryl, heteroaryl arylalkyl and heteroarylalkyl, or Rc and Rd, together with the nitrogen atom to which they are attached, form a heterocyclo group; wherein each alkyl group is optionally interrupted by 1 to 5 atoms selected from the group consisting of â€”Oâ€”, â€”Sâ€” and â€”NRbâ€”, where Rb is alkyl, aryl or heteroaryl; and X is a linker of the formula: â€”Xâ€²â€”Zâ€”(Yâ€²â€”Z)mâ€”Yâ€³â€”Zâ€”Xâ€²â€”â€ƒwherein m is an integer from 0 to 20; Xâ€² at each separate occurrence is selected from the group consisting of â€”Oâ€”, â€”Sâ€”, â€”S(O)â€”, â€”S(O)2â€”, â€”NRâ€²â€”, â€”C(O)â€” and a covalent bond; Z at each separate occurrence is selected from the group consisting of alkylene, cycloalkylene, alkenylene, alkynylene, arylene, heteroarylene and a covalent bond, where the alkylene, cycloalkylene, alkenylene, alkynylene, arylene and heteroarylene groups are optionally substituted with alkyl, cycloalkyl, alkenyl, alkynyl, alkoxy, halo, nitro, aryl, heteroaryl or heterocyclo; Yâ€² and Yâ€³ at each separate occurrence are selected from the group consisting of â€”C(O)NRâ€²â€”, â€”NRâ€²C(O)â€”, â€”NRâ€²C(O)NRâ€²â€”, â€”C(&boxH;NRâ€²)â€”NRâ€²â€”, â€”NRâ€²â€”C(&boxH;NRâ€²)â€”, â€”NRâ€²â€”C(O)â€”Oâ€”, â€”P(O)(ORâ€²)â€”Oâ€”, â€”S(O)nCRâ€²Râ€³â€”, â€”S(O)nâ€”NRâ€²â€”, â€”Sâ€”Sâ€” and a covalent bond; where n is 0, 1 or 2; and Râ€² and Râ€³ at each separate occurrence are selected from the group consisting of hydrogen, alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, aryl, heteroaryl and heterocyclo; or a pharmaceutically acceptable salt thereof.